Core strength, IVT returns to growth
- First quarter fiscal 2027 showed early signs of stabilization for Interventional Technologies, which returned to 3% organic growth.
- The company reorganized its reporting structure into two main segments called MedSurg and Apheresis.
- Total revenue grew 6% organically in the first quarter, driven by strength in Plasma and Blood Management.
- The $86.5 million impairment charge on ensoETM from last year remains a drag on the broader turnaround.
- Future growth relies on the FDA approval and launch of Vivasure's PerQseal Elite closure system.
Good core, signs of healing
Haemonetics has a split story that is starting to show signs of healing. The core Plasma business and Blood Management Technologies continue to carry the company. A recent reorganization into two segments, MedSurg and Apheresis, has cleaned up the narrative after the Whole Blood divestiture.
The most challenging part of the business has been Interventional Technologies, or IVT. The company took an $86.5 million impairment in fiscal 2026 related to ensoETM, an esophageal cooling product hurt by the rise of Pulsed Field Ablation. However, the first quarter of fiscal 2027 offered some relief as IVT returned to 3% organic growth, led by Vascular Closure.
The bull case sees the core businesses throwing off strong cash flow while the IVT stabilization proves that earlier issues were merely execution missteps. The bear case worries that the ensoETM asset will remain a permanent drag. The stock looks like a turnaround story waiting for the launch of Vivasure's PerQseal Elite system to prove its next phase of growth.
Devices, disposables, and hospital tools
Haemonetics sells medical devices, single-use disposables, and software. Plasma centers use its systems to collect plasma and improve yields with tools like Persona PLUS. Hospitals use its surgical products to manage bleeding, recover blood during operations, and close access sites after vascular procedures.
The best parts of the model have repeat use. A machine can lead to recurring disposable sales, and software can tie customers more closely to the platform. The core business funds investment even after a difficult year for IVT, allowing the company to pay down debt and acquire new technologies.
Where the model breaks is also clear. Plasma depends on a limited number of large customers. In Hospital, the Blood Management side is growing, but IVT depends on doctors adopting newer tools and on Haemonetics successfully launching the right products.
What Haemonetics sells
Plasma collection systems and disposables
This includes systems such as NexSys PCS and related disposables for plasma centers, providing a large recurring revenue base.
Persona PLUS plasma technology
Persona PLUS is the next generation of Haemonetics' Persona technology, enabling higher plasma yield per donation and driving recent share gains.
TEG hemostasis management
TEG helps doctors understand a patient's clotting and bleeding risk during procedures such as heart surgery, trauma care, and transplants.
Transfusion and cell salvage tools
These products help hospitals track blood, manage transfusions, and recover a patient's own blood during surgery.
Vascular Closure and PerQseal Elite
Vascular Closure includes products for closing access sites after heart and vascular procedures. Vivasure's PerQseal Elite could expand this area if U.S. approval is granted.
ensoETM esophageal protection
ensoETM cools the esophagus during certain heart ablation procedures. Its market opportunity has shrunk as PFA adoption has grown.
Fiscal 2027 first quarter mix
This mix uses first quarter fiscal 2027 net revenue under the company's new two-segment structure. Apheresis is now the larger segment, containing the core Plasma business.
What could break the thesis
PFA keeps shrinking ensoETM
High impact · High oddsPulsed Field Ablation is a newer method for treating atrial fibrillation. Haemonetics says one perceived benefit is that it may spare the esophagus, which can reduce the need for esophageal cooling. The $86.5 million impairment shows this risk has already hit the company.
Vivasure launch disappoints
High impact · Medium oddsHaemonetics bought Vivasure in January 2026. The company has submitted a PMA application to the FDA for a U.S. arterial indication for PerQseal Elite. If approval is delayed or adoption is slow, the IVT recovery has fewer paths forward.
Debt limits flexibility
Medium impact · Medium oddsHaemonetics carries significant debt across term loans and convertible notes. Debt service can limit choices if growth slows, interest rates change, or if more restructuring is needed.
Large customers move slowly or leave
Medium impact · Medium oddsPlasma revenue is tied to a small group of large customers. The CSL transition already weighed on prior revenue. Even when the underlying products are strong, a big customer change can hide that strength for several quarters.
In one breath
What does Haemonetics do?
Haemonetics makes medical technology for plasma centers, blood centers, and hospitals. Its products help collect plasma, process blood components, manage bleeding, recover blood during surgery, and track transfusions.
Why did the Haemonetics thesis get more cautious last year?
The core business performed well, but Interventional Technologies was weaker than expected. The company recorded an $86.5 million impairment tied mostly to Attune Medical and ensoETM because a new ablation method may reduce the need for esophageal cooling.
What is PerQseal Elite?
PerQseal Elite is Vivasure's large-bore vessel closure system. It is designed to close large access sites after procedures such as TAVR and EVAR, and U.S. FDA approval is a major near-term priority.
